Ramin Hosseinzadeh1, Mohammad Ali Sheikh Beig Goharrizi2, Mansour Bahardoust3,4, Akbar Ghorbani Alvanegh5, Mohammad Reza Ataee6, Mehdi Bagheri7, Ensiyeh Shabani Navidiyan8, Seyed Reza Hosseini Zijoud9, Mohammad Heiat10. 1. Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran. 2. Atherosclerosis Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. 3. Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran. Mansourbahari93@gmail.com. 4. Department of Epidemiology, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Mansourbahari93@gmail.com. 5. Human Genetics Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran. 6. Applied Microbiology Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. 7. Chemical Injuries Research Center, Systems Biology and Poisonings Institute, Baqiyatallah University of Medical Sciences, Tehran, Iran. 8. Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran. 9. Clinical Research Development Unit, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 10. Baqiyatallah Research Center for Gastroenterology and Liver Diseases, Baqiyatallah University of Medical Sciences, Tehran, Iran. Mohamad.heiat@gmail.com.
Abstract
BACKGROUND: Hypertension, the most common comorbidity among coronavirus disease 2019 (COVID-19) patients, is accompanied by worse clinical outcomes, but there is lack of evidence about prognostic factors among COVID-19 patients with hypertension. We have come up with some prognostic factors to predict the severity of COVID-19 among hypertensive patients. In addition, epidemiologic, clinical and laboratory differences among COVID-19 patients with and without underlying hypertension were evaluated. METHODS: Medical profiles of 598 COVID-19 cases were analyzed. Patients were divided into two comparative groups according to their positive or negative history of hypertension. Then, epidemiologic, clinical, laboratory and radiological features and also clinical outcomes were compared. RESULTS: 176 (29.4%) patients had underlying hypertension. Diabetes was significantly higher in hypertensive group [72 (40.9%) vs 76 (18%)] (P-value: 0.001). Cardiovascular and renal disorders were significantly higher in hypertensive patients. (P-value: 0.001 and 0.013 respectively). In COVID-19 patients with hypertension, severe/critical types were significantly higher. [42(23.8%) vs. 41(9.7%)], (P-value: 0.012). In the logistic regression model, Body mass index > 25 (ORAdj: 1.8, 95% CI: 1.2 to 2.42; P-value: 0.027), age over 60 (ORAdj: 1.26, 95% CI: 1.08 to 1.42; P-value: 0.021), increased hospitalization period (ORAdj: 2.1, 95% CI: 1.24 to 2.97; P-value: 0.013), type 2 diabetes (ORAdj: 2.22, 95% CI: 1.15 to 3.31; P-value: 0.001) and chronic kidney disease (ORAdj: 1.83, 95% CI: 1.19 to 2.21; P-value: 0.013) were related with progression of COVID-19. CONCLUSION: Hypertensive patients with Age > 60-year-old, BMI > 25 Kg/m2, CVD, diabetes and chronic kidney disease are associated with poor outcomes in those with COVID-19 infection.
BACKGROUND:Hypertension, the most common comorbidity among coronavirus disease 2019 (COVID-19) patients, is accompanied by worse clinical outcomes, but there is lack of evidence about prognostic factors among COVID-19patients with hypertension. We have come up with some prognostic factors to predict the severity of COVID-19 among hypertensivepatients. In addition, epidemiologic, clinical and laboratory differences among COVID-19patients with and without underlying hypertension were evaluated. METHODS: Medical profiles of 598 COVID-19 cases were analyzed. Patients were divided into two comparative groups according to their positive or negative history of hypertension. Then, epidemiologic, clinical, laboratory and radiological features and also clinical outcomes were compared. RESULTS: 176 (29.4%) patients had underlying hypertension. Diabetes was significantly higher in hypertensive group [72 (40.9%) vs 76 (18%)] (P-value: 0.001). Cardiovascular and renal disorders were significantly higher in hypertensivepatients. (P-value: 0.001 and 0.013 respectively). In COVID-19patients with hypertension, severe/critical types were significantly higher. [42(23.8%) vs. 41(9.7%)], (P-value: 0.012). In the logistic regression model, Body mass index > 25 (ORAdj: 1.8, 95% CI: 1.2 to 2.42; P-value: 0.027), age over 60 (ORAdj: 1.26, 95% CI: 1.08 to 1.42; P-value: 0.021), increased hospitalization period (ORAdj: 2.1, 95% CI: 1.24 to 2.97; P-value: 0.013), type 2 diabetes (ORAdj: 2.22, 95% CI: 1.15 to 3.31; P-value: 0.001) and chronic kidney disease (ORAdj: 1.83, 95% CI: 1.19 to 2.21; P-value: 0.013) were related with progression of COVID-19. CONCLUSION:Hypertensivepatients with Age > 60-year-old, BMI > 25 Kg/m2, CVD, diabetes and chronic kidney disease are associated with poor outcomes in those with COVID-19infection.
Entities:
Keywords:
Hypertension; Risk factor; Severe COVID-19
Authors: Master R O Chisale; Billy W Nyambalo; Collins Mitambo; Pizga Kumwenda; Saul E Mwale; Balwani Chingatichifwe Mbakaya Journal: IJID Reg Date: 2021-11-22
Authors: Jonás Carmona-Pírez; Ignatios Ioakeim-Skoufa; Antonio Gimeno-Miguel; Beatriz Poblador-Plou; Francisca González-Rubio; Dolores Muñoyerro-Muñiz; Juliana Rodríguez-Herrera; Juan Antonio Goicoechea-Salazar; Alexandra Prados-Torres; Román Villegas-Portero Journal: Int J Environ Res Public Health Date: 2022-03-23 Impact factor: 3.390
Authors: Samantha L Cooper; Eleanor Boyle; Sophie R Jefferson; Calum R A Heslop; Pirathini Mohan; Gearry G J Mohanraj; Hamza A Sidow; Rory C P Tan; Stephen J Hill; Jeanette Woolard Journal: Int J Mol Sci Date: 2021-07-31 Impact factor: 6.208